AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab
Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 144
- Registration Number
- NCT04884269
- Locations
- 🇯🇵
Research Site, Wakayama, Japan
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
Phase 3
Active, not recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 367
- Registration Number
- NCT04877691
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222
Terminated
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- Other: None (Observational study)
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT04877743
- Locations
- 🇩🇪
Research Site, Essen, Germany
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
Completed
- Conditions
- Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 104
- Registration Number
- NCT04872621
- Locations
- 🇯🇵
Research Site, Yamaguchi, Japan
A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Small Cell Lung CancerNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT04870112
- Locations
- 🇨🇳
Research Site, Taipei City, Taiwan
Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform
Not Applicable
Completed
- Conditions
- Asthma
- Interventions
- Device: AMAZE™ ApplicationDevice: AMAZE™ Dashboard
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT04868500
- Locations
- 🇺🇸
Research Site, Boston, Massachusetts, United States
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT04865419
- Locations
- 🇰🇷
Research Site, Busan, Korea, Republic of
Forxiga HF General Drug Use-Results Study
Completed
- Conditions
- Heart Failure
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1221
- Registration Number
- NCT04865406
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Phase 3
Recruiting
- Conditions
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 895
- Registration Number
- NCT04862663
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- Other: None (Observational study)
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 763
- Registration Number
- NCT04857619
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
© Copyright 2025. All Rights Reserved by MedPath